Chad Jansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chad Jansen has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Alexander J. Stokes
John A. Burns School of Medicine
5 shared publications - Helen Turner
Laboratory of Pharmacology and Analytics, Biology and Data Science Programs, School of Natural Sciences and Mathematics, Chaminade University
5 shared publications - Andrea L. Small-Howard
GBS Global Biopharma, Ottawa, ON K2H 7L1, Canada
4 shared publications - Chaker N. Adra
The Adra Institute, Boston, MA 02215, USA
4 shared publications - Julia Howard
Laboratory of Pharmacology and Analytics, Biology and Data Science Programs, School of Natural Sciences and Mathematics, Chaminade University, Honolulu, HI 96816, USA
3 shared publications B. Wooton
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by IOP Publishing in Machine Learning: Health
- Vol. 2 (2) , 025017
Utilizing categorical boosting and SHAP to understand key predictors of frequency of use at discharge for completed substance abuse treatments in TEDS-D
Background: Substance use disorder is a pressing US public health crisis, with 48.7 million people reporting past-year substance use and over 100 000 overdose deaths in 2022. Building on a growing body of machine learning research using the SAMHSA treatment episode Data set—discharges (TEDS-D), this study introduces frequency of use at discharge as an outcome variable and the inclusion of U.S. state as a predictor. Research Design and Methods: First, reason for discharge was evaluated as a dependent variable and compared to frequency of use at discharge. Utilizing 2411 351 completed treatment episodes from TEDS-D 2015–2019, a categorical boosting model was employed to predict frequency of substance use at discharge using 62 predictor variables. Shapley additive explanations (SHAP) calculated global feature importance and decomposed individual predictions. State-level models were compared to the national model using rank-biased overlap (RBO), with a Hawai’i case study demonstrating state-level decision support. Results: Although treatment completion yielded higher rates of no use at discharge than dropout (45% vs 28%), 25% of completed episodes reported active substance use, 9% reported homelessness, and 50% reported unemployment at discharge. The model demonstrated strong predictive performance (AUC = 0.96, sensitivity = 0.85, specificity = 0.95). Treatment and geographic factors outweighed patient attributes, with frequency of use at admission, U.S state of treatment, length of stay, and service type as the four most important features. Among all service types, long-term residential rehabilitation was associated with the lowest SHAP values and predicted probability of substance use at discharge. State-stratified models showed moderate feature importance consistency (mean RBO = 0.59, range: 0.30–0.73). The Hawai’i case study identified elevated probability of use at discharge for younger clients and revealed substantial underreporting of long-term residential and therapeutic community treatment modalities in federal data. Discussion and Implications: State-level variability in treatment outcomes reflects systemic inconsistencies in policy, reporting, and service access that complicate national benchmarking and may obscure the true drivers of patient recovery. Explainable ML provides actionable insights for tailoring treatment and informing data-driven policy to improve outcomes.
- 7 October 2026
- Published by IOP Publishing in Machine Learning: Health
- Vol. 2 (2) , 025017
Open AccessUtilizing categorical boosting and SHAP to understand key predictors of frequency of use at discharge for completed substance abuse treatments in TEDS-D
Background: Substance use disorder is a pressing US public health crisis, with 48.7 million people reporting past-year substance use and over 100 000 overdose deaths in 2022. Building on a growing body of machine learning research using the SAMHSA treatment episode Data set—discharges (TEDS-D), this study introduces frequency of use at discharge as an outcome variable and the inclusion of U.S. state as a predictor. Research Design and Methods: First, reason for discharge was evaluated as a dependent variable and compared to frequency of use at discharge. Utilizing 2411 351 completed treatment episodes from TEDS-D 2015–2019, a categorical boosting model was employed to predict frequency of substance use at discharge using 62 predictor variables. Shapley additive explanations (SHAP) calculated global feature importance and decomposed individual predictions. State-level models were compared to the national model using rank-biased overlap (RBO), with a Hawai’i case study demonstrating state-level decision support. Results: Although treatment completion yielded higher rates of no use at discharge than dropout (45% vs 28%), 25% of completed episodes reported active substance use, 9% reported homelessness, and 50% reported unemployment at discharge. The model demonstrated strong predictive performance (AUC = 0.96, sensitivity = 0.85, specificity = 0.95). Treatment and geographic factors outweighed patient attributes, with frequency of use at admission, U.S state of treatment, length of stay, and service type as the four most important features. Among all service types, long-term residential rehabilitation was associated with the lowest SHAP values and predicted probability of substance use at discharge. State-stratified models showed moderate feature importance consistency (mean RBO = 0.59, range: 0.30–0.73). The Hawai’i case study identified elevated probability of use at discharge for younger clients and revealed substantial underreporting of long-term residential and therapeutic community treatment modalities in federal data. Discussion and Implications: State-level variability in treatment outcomes reflects systemic inconsistencies in policy, reporting, and service access that complicate national benchmarking and may obscure the true drivers of patient recovery. Explainable ML provides actionable insights for tailoring treatment and informing data-driven policy to improve outcomes.
- Open Access
Evidence and Tradition in Dialogue: Biological Sex Variability in Phytomedicine Research as a Foundation for Safety, Efficacy, and Robust Evidence Standards
Background: Incorporating sex as a biological variable (SBV) is recognized as essential for improving the reliability, reproducibility, and generalizability of pharmacological research. This principle is codified in international policies and guidelines, yet implementation remains uneven, especially in phytomedicine. Phytomedicines are a major component of healthcare worldwide, with 65% of the global population relying on them in both regulated and traditional contexts. Globally, phytomedicines are used by males, females, intersex and non-cis gender persons, all of whom may present specific safety and efficacy considerations and warrant full inclusion in pre-clinical to clinical research pipelines. However, in contemporary settings, phytomedicine lags in SBV best practices relative to Western allopathic standards for research design. Methods: We conducted a non-systematic review and in silico data mining to quantify sex/gender representation in recent preclinical and clinical phytomedicine studies, complemented by targeted case studies of sexually dimorphic safety/efficacy. We also summarize the historical role of women and gender-diverse people as users and providers within Traditional and Integrative Medical Systems (TIMSs). Results: Across rodent and human studies, females are under-represented relative to males, and sex is rarely reported for cell lines. Intentional inclusion of intersex and other gender-diverse populations is largely absent. Case studies illustrate plausible sex-associated differences in pharmacokinetics, pharmacodynamics, and adverse event profiles. TIMSs historically address women’s health needs and include substantial participation by female practitioners; however, contemporary SBV practices remain less standardized than in Western allopathic pipelines. Conclusions: SBV integration in phytomedicine is needed to strengthen safety, efficacy, and regulatory-grade evidence. Practical barriers include legacy datasets without sex metadata, limited intersex animal models, and uneven resources across settings. We outline feasible, stepwise practices to improve SBV adoption in a manner compatible with TIMS contexts and recommend expanding current guidelines to better support diverse research environments while maintaining scientific rigor.
Open AccessEvidence and Tradition in Dialogue: Biological Sex Variability in Phytomedicine Research as a Foundation for Safety, Efficacy, and Robust Evidence Standards
Background: Incorporating sex as a biological variable (SBV) is recognized as essential for improving the reliability, reproducibility, and generalizability of pharmacological research. This principle is codified in international policies and guidelines, yet implementation remains uneven, especially in phytomedicine. Phytomedicines are a major component of healthcare worldwide, with 65% of the global population relying on them in both regulated and traditional contexts. Globally, phytomedicines are used by males, females, intersex and non-cis gender persons, all of whom may present specific safety and efficacy considerations and warrant full inclusion in pre-clinical to clinical research pipelines. However, in contemporary settings, phytomedicine lags in SBV best practices relative to Western allopathic standards for research design. Methods: We conducted a non-systematic review and in silico data mining to quantify sex/gender representation in recent preclinical and clinical phytomedicine studies, complemented by targeted case studies of sexually dimorphic safety/efficacy. We also summarize the historical role of women and gender-diverse people as users and providers within Traditional and Integrative Medical Systems (TIMSs). Results: Across rodent and human studies, females are under-represented relative to males, and sex is rarely reported for cell lines. Intentional inclusion of intersex and other gender-diverse populations is largely absent. Case studies illustrate plausible sex-associated differences in pharmacokinetics, pharmacodynamics, and adverse event profiles. TIMSs historically address women’s health needs and include substantial participation by female practitioners; however, contemporary SBV practices remain less standardized than in Western allopathic pipelines. Conclusions: SBV integration in phytomedicine is needed to strengthen safety, efficacy, and regulatory-grade evidence. Practical barriers include legacy datasets without sex metadata, limited intersex animal models, and uneven resources across settings. We outline feasible, stepwise practices to improve SBV adoption in a manner compatible with TIMS contexts and recommend expanding current guidelines to better support diverse research environments while maintaining scientific rigor.
- Open Access
A pathway to next-generation mast cell stabilizers identified through the novel Phytomedical Analytics for Research Optimization at Scale data platform
Mast cell stabilizers (MCS) have the potential to address unmet therapeutic need in allergy and inflammation management. MCS chronically suppress all arms of the pro-inflammatory mast cell response to stimulation (e.g., histamine, protease, lipid mediators, cytokines, chemokines). They may therefore outperform approaches such as H1, H2 and H4 inhibitors (antihistamines) which block only the acute histamine release by mast cells and leave the rest of the functional response untouched. Despite their potential, current MCS (e.g., cromolyn sodium, Tranilast, nedocromil) in clinical use are hindered by poor bioavailability, frequent dosing, long lags to onset of relief, and enigmatic mechanisms of action. MCS have their origins in phytomedicine: cromolyn sodium is the longest standing drug in the class and is a derivatized form of Khellin from Ammi visnaga, used as an anti-inflammatory. Other phytopharmacopeias may offer candidate ‘next generation’ MCS (ngMCS) and in this study we hypothesized that a coupled pharmacoanalytic and in vitro pharmacology approach could be used to identify, prioritize and derisk additional candidate MCS from phytomedical sources for later pre-clinical and clinical evaluation. Here, we report a novel data analytics workflow starting with a newly developed phytopharmacopeia data platform with >3.5B linkage pathways (country → medical system → formulation → indication → ingredient organism → chemical component → other parameters), covering 22 M sq. miles of biogeography and historical and contemporary timeframes. Additional data layers include druggability indices, target and pathway analyses. The current study validates a subset of candidate phytomedical ngMCS using in silico workflow and in vitro pharmacology, and develops a new harmonic mean-based ‘MCS score’ for further streamlining of the candidate prioritization process. This proof-of-concept study may have particular relevance for complex presentations such as Mast Cell Activation Syndrome (MCAS) where ngMCS may outperform current management approaches.
Open AccessA pathway to next-generation mast cell stabilizers identified through the novel Phytomedical Analytics for Research Optimization at Scale data platform
Mast cell stabilizers (MCS) have the potential to address unmet therapeutic need in allergy and inflammation management. MCS chronically suppress all arms of the pro-inflammatory mast cell response to stimulation (e.g., histamine, protease, lipid mediators, cytokines, chemokines). They may therefore outperform approaches such as H1, H2 and H4 inhibitors (antihistamines) which block only the acute histamine release by mast cells and leave the rest of the functional response untouched. Despite their potential, current MCS (e.g., cromolyn sodium, Tranilast, nedocromil) in clinical use are hindered by poor bioavailability, frequent dosing, long lags to onset of relief, and enigmatic mechanisms of action. MCS have their origins in phytomedicine: cromolyn sodium is the longest standing drug in the class and is a derivatized form of Khellin from Ammi visnaga, used as an anti-inflammatory. Other phytopharmacopeias may offer candidate ‘next generation’ MCS (ngMCS) and in this study we hypothesized that a coupled pharmacoanalytic and in vitro pharmacology approach could be used to identify, prioritize and derisk additional candidate MCS from phytomedical sources for later pre-clinical and clinical evaluation. Here, we report a novel data analytics workflow starting with a newly developed phytopharmacopeia data platform with >3.5B linkage pathways (country → medical system → formulation → indication → ingredient organism → chemical component → other parameters), covering 22 M sq. miles of biogeography and historical and contemporary timeframes. Additional data layers include druggability indices, target and pathway analyses. The current study validates a subset of candidate phytomedical ngMCS using in silico workflow and in vitro pharmacology, and develops a new harmonic mean-based ‘MCS score’ for further streamlining of the candidate prioritization process. This proof-of-concept study may have particular relevance for complex presentations such as Mast Cell Activation Syndrome (MCAS) where ngMCS may outperform current management approaches.
- Open Access
Computational analysis of therapeutic potential for simplified Piper. spp- derived medicinal mixtures in anxiety, sleep, pain and seizure
Phytomedicines have played a vital role in traditional medical systems globally, particularly in providing culturally relevant and accessible healthcare solutions. Piper methysticum , known as Kava, is a traditional Pacific Island phytomedicine with clinically validated anxiolytic properties, primarily attributed to its Kavalactones. However, the biogeographically restricted distribution of Piper methysticum and the ecological and cultural concerns surrounding its widespread adoption highlight the need to explore alternative sources within the Piper genus. This study investigates whether other species within the Piper genus, used phytomedically in non-Pacific contexts, exhibit similar therapeutic efficacy for anxiety, stress, and related disorders including Post-Traumatic Stress Disorder (PTSD). We employed a computational approach utilizing a novel data platform of non-Western phytomedical pharmacopeias to analyze the secondary metabolomes of various Piper species. Network analysis and multidimensional data projections were used to compare the chemical composition and therapeutic indications of these species with those of Piper methysticum . Our findings suggest that while Kavalactones are predominantly unique to Piper methysticum , other Piper species also contain bioactive compounds associated with anxiolytic and stress-relieving effects. These results provide insight into the potential for culturally and biogeographically contextualized approaches to PTSD treatment, beyond the exclusive use of Kava, and lay the groundwork for future research into alternative phytomedicinal therapies within the Piper genus.
Open AccessComputational analysis of therapeutic potential for simplified Piper. spp- derived medicinal mixtures in anxiety, sleep, pain and seizure
Phytomedicines have played a vital role in traditional medical systems globally, particularly in providing culturally relevant and accessible healthcare solutions. Piper methysticum , known as Kava, is a traditional Pacific Island phytomedicine with clinically validated anxiolytic properties, primarily attributed to its Kavalactones. However, the biogeographically restricted distribution of Piper methysticum and the ecological and cultural concerns surrounding its widespread adoption highlight the need to explore alternative sources within the Piper genus. This study investigates whether other species within the Piper genus, used phytomedically in non-Pacific contexts, exhibit similar therapeutic efficacy for anxiety, stress, and related disorders including Post-Traumatic Stress Disorder (PTSD). We employed a computational approach utilizing a novel data platform of non-Western phytomedical pharmacopeias to analyze the secondary metabolomes of various Piper species. Network analysis and multidimensional data projections were used to compare the chemical composition and therapeutic indications of these species with those of Piper methysticum . Our findings suggest that while Kavalactones are predominantly unique to Piper methysticum , other Piper species also contain bioactive compounds associated with anxiolytic and stress-relieving effects. These results provide insight into the potential for culturally and biogeographically contextualized approaches to PTSD treatment, beyond the exclusive use of Kava, and lay the groundwork for future research into alternative phytomedicinal therapies within the Piper genus.
- Open Access
- 29 January 2022
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 616, 121524
Potential use for chronic pain: Poly(Ethylene Glycol)-Poly(Lactic-Co-Glycolic Acid) nanoparticles enhance the effects of Cannabis-Based terpenes on calcium influx in TRPV1-Expressing cells
- 29 January 2022
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 616, 121524
Open AccessPotential use for chronic pain: Poly(Ethylene Glycol)-Poly(Lactic-Co-Glycolic Acid) nanoparticles enhance the effects of Cannabis-Based terpenes on calcium influx in TRPV1-Expressing cells
- Open Access
- 1 March 2021
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 267, 113477
Medicine in motion: Opportunities, challenges and data analytics-based solutions for traditional medicine integration into western medical practice
- 1 March 2021
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 267, 113477
Open AccessMedicine in motion: Opportunities, challenges and data analytics-based solutions for traditional medicine integration into western medical practice